Your search for rivaroxaban returned 152 results

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

Janssen Research & Development announced today that it has submitted the Complete Response to the FDA for the use of Xarelto (rivaroxaban) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of August. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of November. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The summary below gives an overview of some of the important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of the 118 key monograph updates made this month (not an inclusive list).

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of November. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.

The new sNDA submission is supported by the ‘Einstein Choice’ study, which included 3,365 patients in a Phase 3 randomized, double-blind study that compared Xarelto once daily to aspirin.

Janssen announced that the FDA has issued a second complete response letter regarding a supplemental New Drug Application for Xarelto (rivaroxaban) for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome.